Fig. 3From: Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study(a) Patient distribution and (b) CKD stage distribution (where reported) across the study cohorts in the MRA population CKD chronic kidney disease, DKD diabetic kidney disease, ESRD end-stage renal disease, HF heart failure, MRA mineralocorticoid receptor antagonistBack to article page